Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

GALAD score predicts NASH-HCC more than a year in advance

Key clinical point: For patients with nonalcoholic steatohepatitis (NASH), the GALAD score is a highly accurate method of predicting hepatocellular carcinoma (HCC).

Major finding: The GALAD score predicted any-stage NASH-HCC with an area under the curve (AUC) of 0.96.

Study details: A retrospective case-control study and prospective phase 3 trial involving 749 patients with NASH.

Disclosures: The study was funded by Deutsche Forschungsgemeinschaft, the Wilhelm-Laupitz Foundation, and the Werner Jackstaedt Foundation. The investigators declared no conflicts of interest.

Citation:

Best J et al. Clin Gastro Hepatol. 2019 Nov 8. doi: 10.1016/j.cgh.2019.11.012.